Kylin Management Exits Position in China Biologic Products Inc (CBPO)

China Biologic Products Inc (CBPO) : Kylin Management has sold out all of its stake in China Biologic Products Inc during the most recent quarter, according to the disclosure filed by the company on May 13, 2016 with the SEC. The investment management company has sold out 1,800 shares of China Biologic Products Inc which is valued at $207,018.

Other Hedge Funds, Including , Bogle Investment Management L P De sold out all of its stake in CBPO during the most recent quarter. The investment firm sold 88,870 shares of CBPO which is valued $10.2 Million.Group One Trading boosted its stake in CBPO in the latest quarter, The investment management firm added 200 additional shares and now holds a total of 2,785 shares of China Biologic Products Inc which is valued at $320,303. China Biologic Products Inc makes up approx 0.04% of Group One Trading’s portfolio.Gsa Capital Partners Llp reduced its stake in CBPO by selling 2,799 shares or 6.47% in the most recent quarter. The Hedge Fund company now holds 40,495 shares of CBPO which is valued at $4.7 Million. China Biologic Products Inc makes up approx 0.30% of Gsa Capital Partners Llp’s portfolio.Blackrock Japan Ltd reduced its stake in CBPO by selling 29 shares or 29.59% in the most recent quarter. The Hedge Fund company now holds 69 shares of CBPO which is valued at $7,936.Blackrock Advisors reduced its stake in CBPO by selling 2,482 shares or 35.18% in the most recent quarter. The Hedge Fund company now holds 4,574 shares of CBPO which is valued at $526,056.

China Biologic Products Inc closed down -0.64 points or -0.55% at $114.84 with 2,77,948 shares getting traded on Wednesday. Post opening the session at $115.55, the shares hit an intraday low of $114.04 and an intraday high of $115.86 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

On the company’s financial health, China Biologic Products Inc reported $1.09 EPS for the quarter, beating the analyst consensus estimate by $ 0.21 according to the earnings call on May 4, 2016. Analyst had a consensus of $0.88. The company had revenue of $85.60 million for the quarter.The company’s revenue was up 21.6% compared to the same quarter last year.

Many Wall Street Analysts have commented on China Biologic Products Inc. China Biologic Products Inc was Downgraded by Credit Suisse to ” Neutral” on Mar 1, 2016.

China Biologic Products Inc. (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research development manufacturing and sales of human plasma-based biopharmaceutical products in China. China Biologic has a product portfolio with over 20 different dosage forms of plasma products. The Company’s principal products are human albumin and immunoglobulin for intravenous injection (IVIG). China Biologic operates its business through two subsidiaries namely Shandong Taibang Biological Products Co. Ltd. and Guizhou Taibang Biological Products Co. Ltd. The Company also holds an interest in Xi’an Huitian Blood Products Co. Ltd. a plasma products company. Its products include human albumin human immunoglobulin IVIG thymopolypeptides injection human hepatitis B immunoglobulin human rabies immunoglobulin human tetanus immunoglobulin placenta polypeptide Factor VIII and human prothrombin complex concentrate (PCC).

Leave a Reply

China Biologic Products Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on China Biologic Products Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.